Ulcerative Colitis Treatment Options Market, Global Outlook and Forecast 2022-2028

July 2022 | 102 pages | ID: U33B09A01F42EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Ulcerative Colitis Treatment Options in Global, including the following market information:

Global Ulcerative Colitis Treatment Options Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Ulcerative Colitis Treatment Options market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Anti-inflammatory Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Ulcerative Colitis Treatment Options include Pfizer, Novartis, Roche, Sanofi, GSK, AstraZeneca, MSD, Johnson & Johnson and Bayer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Ulcerative Colitis Treatment Options companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Ulcerative Colitis Treatment Options Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Ulcerative Colitis Treatment Options Market Segment Percentages, by Type, 2021 (%)

• Anti-inflammatory Drugs
• Immune System Suppressors
• Other Medications

Global Ulcerative Colitis Treatment Options Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Ulcerative Colitis Treatment Options Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinic
• Drugs Store
• Others

Global Ulcerative Colitis Treatment Options Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Ulcerative Colitis Treatment Options Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Ulcerative Colitis Treatment Options revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Ulcerative Colitis Treatment Options revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Pfizer
• Novartis
• Roche
• Sanofi
• GSK
• AstraZeneca
• MSD
• Johnson & Johnson
• Bayer
• AbbVie
• Eli Lilly and Company
• Amgen
• Takeda Pharmaceuticals Company
• Ferring Pharmaceuticals
• InDeX Pharmaceuticals

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Ulcerative Colitis Treatment Options Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Ulcerative Colitis Treatment Options Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL ULCERATIVE COLITIS TREATMENT OPTIONS OVERALL MARKET SIZE

2.1 Global Ulcerative Colitis Treatment Options Market Size: 2021 VS 2028
2.2 Global Ulcerative Colitis Treatment Options Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Ulcerative Colitis Treatment Options Players in Global Market
3.2 Top Global Ulcerative Colitis Treatment Options Companies Ranked by Revenue
3.3 Global Ulcerative Colitis Treatment Options Revenue by Companies
3.4 Top 3 and Top 5 Ulcerative Colitis Treatment Options Companies in Global Market, by Revenue in 2021
3.5 Global Companies Ulcerative Colitis Treatment Options Product Type
3.6 Tier 1, Tier 2 and Tier 3 Ulcerative Colitis Treatment Options Players in Global Market
  3.6.1 List of Global Tier 1 Ulcerative Colitis Treatment Options Companies
  3.6.2 List of Global Tier 2 and Tier 3 Ulcerative Colitis Treatment Options Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Ulcerative Colitis Treatment Options Market Size Markets, 2021 & 2028
  4.1.2 Anti-inflammatory Drugs
  4.1.3 Immune System Suppressors
  4.1.4 Other Medications
4.2 By Type - Global Ulcerative Colitis Treatment Options Revenue & Forecasts
  4.2.1 By Type - Global Ulcerative Colitis Treatment Options Revenue, 2017-2022
  4.2.2 By Type - Global Ulcerative Colitis Treatment Options Revenue, 2023-2028
  4.2.3 By Type - Global Ulcerative Colitis Treatment Options Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Ulcerative Colitis Treatment Options Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Clinic
  5.1.4 Drugs Store
  5.1.5 Others
5.2 By Application - Global Ulcerative Colitis Treatment Options Revenue & Forecasts
  5.2.1 By Application - Global Ulcerative Colitis Treatment Options Revenue, 2017-2022
  5.2.2 By Application - Global Ulcerative Colitis Treatment Options Revenue, 2023-2028
  5.2.3 By Application - Global Ulcerative Colitis Treatment Options Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Ulcerative Colitis Treatment Options Market Size, 2021 & 2028
6.2 By Region - Global Ulcerative Colitis Treatment Options Revenue & Forecasts
  6.2.1 By Region - Global Ulcerative Colitis Treatment Options Revenue, 2017-2022
  6.2.2 By Region - Global Ulcerative Colitis Treatment Options Revenue, 2023-2028
  6.2.3 By Region - Global Ulcerative Colitis Treatment Options Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Ulcerative Colitis Treatment Options Revenue, 2017-2028
  6.3.2 US Ulcerative Colitis Treatment Options Market Size, 2017-2028
  6.3.3 Canada Ulcerative Colitis Treatment Options Market Size, 2017-2028
  6.3.4 Mexico Ulcerative Colitis Treatment Options Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Ulcerative Colitis Treatment Options Revenue, 2017-2028
  6.4.2 Germany Ulcerative Colitis Treatment Options Market Size, 2017-2028
  6.4.3 France Ulcerative Colitis Treatment Options Market Size, 2017-2028
  6.4.4 U.K. Ulcerative Colitis Treatment Options Market Size, 2017-2028
  6.4.5 Italy Ulcerative Colitis Treatment Options Market Size, 2017-2028
  6.4.6 Russia Ulcerative Colitis Treatment Options Market Size, 2017-2028
  6.4.7 Nordic Countries Ulcerative Colitis Treatment Options Market Size, 2017-2028
  6.4.8 Benelux Ulcerative Colitis Treatment Options Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Ulcerative Colitis Treatment Options Revenue, 2017-2028
  6.5.2 China Ulcerative Colitis Treatment Options Market Size, 2017-2028
  6.5.3 Japan Ulcerative Colitis Treatment Options Market Size, 2017-2028
  6.5.4 South Korea Ulcerative Colitis Treatment Options Market Size, 2017-2028
  6.5.5 Southeast Asia Ulcerative Colitis Treatment Options Market Size, 2017-2028
  6.5.6 India Ulcerative Colitis Treatment Options Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Ulcerative Colitis Treatment Options Revenue, 2017-2028
  6.6.2 Brazil Ulcerative Colitis Treatment Options Market Size, 2017-2028
  6.6.3 Argentina Ulcerative Colitis Treatment Options Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Ulcerative Colitis Treatment Options Revenue, 2017-2028
  6.7.2 Turkey Ulcerative Colitis Treatment Options Market Size, 2017-2028
  6.7.3 Israel Ulcerative Colitis Treatment Options Market Size, 2017-2028
  6.7.4 Saudi Arabia Ulcerative Colitis Treatment Options Market Size, 2017-2028
  6.7.5 UAE Ulcerative Colitis Treatment Options Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Pfizer
  7.1.1 Pfizer Corporate Summary
  7.1.2 Pfizer Business Overview
  7.1.3 Pfizer Ulcerative Colitis Treatment Options Major Product Offerings
  7.1.4 Pfizer Ulcerative Colitis Treatment Options Revenue in Global Market (2017-2022)
  7.1.5 Pfizer Key News
7.2 Novartis
  7.2.1 Novartis Corporate Summary
  7.2.2 Novartis Business Overview
  7.2.3 Novartis Ulcerative Colitis Treatment Options Major Product Offerings
  7.2.4 Novartis Ulcerative Colitis Treatment Options Revenue in Global Market (2017-2022)
  7.2.5 Novartis Key News
7.3 Roche
  7.3.1 Roche Corporate Summary
  7.3.2 Roche Business Overview
  7.3.3 Roche Ulcerative Colitis Treatment Options Major Product Offerings
  7.3.4 Roche Ulcerative Colitis Treatment Options Revenue in Global Market (2017-2022)
  7.3.5 Roche Key News
7.4 Sanofi
  7.4.1 Sanofi Corporate Summary
  7.4.2 Sanofi Business Overview
  7.4.3 Sanofi Ulcerative Colitis Treatment Options Major Product Offerings
  7.4.4 Sanofi Ulcerative Colitis Treatment Options Revenue in Global Market (2017-2022)
  7.4.5 Sanofi Key News
7.5 GSK
  7.5.1 GSK Corporate Summary
  7.5.2 GSK Business Overview
  7.5.3 GSK Ulcerative Colitis Treatment Options Major Product Offerings
  7.5.4 GSK Ulcerative Colitis Treatment Options Revenue in Global Market (2017-2022)
  7.5.5 GSK Key News
7.6 AstraZeneca
  7.6.1 AstraZeneca Corporate Summary
  7.6.2 AstraZeneca Business Overview
  7.6.3 AstraZeneca Ulcerative Colitis Treatment Options Major Product Offerings
  7.6.4 AstraZeneca Ulcerative Colitis Treatment Options Revenue in Global Market (2017-2022)
  7.6.5 AstraZeneca Key News
7.7 MSD
  7.7.1 MSD Corporate Summary
  7.7.2 MSD Business Overview
  7.7.3 MSD Ulcerative Colitis Treatment Options Major Product Offerings
  7.7.4 MSD Ulcerative Colitis Treatment Options Revenue in Global Market (2017-2022)
  7.7.5 MSD Key News
7.8 Johnson & Johnson
  7.8.1 Johnson & Johnson Corporate Summary
  7.8.2 Johnson & Johnson Business Overview
  7.8.3 Johnson & Johnson Ulcerative Colitis Treatment Options Major Product Offerings
  7.8.4 Johnson & Johnson Ulcerative Colitis Treatment Options Revenue in Global Market (2017-2022)
  7.8.5 Johnson & Johnson Key News
7.9 Bayer
  7.9.1 Bayer Corporate Summary
  7.9.2 Bayer Business Overview
  7.9.3 Bayer Ulcerative Colitis Treatment Options Major Product Offerings
  7.9.4 Bayer Ulcerative Colitis Treatment Options Revenue in Global Market (2017-2022)
  7.9.5 Bayer Key News
7.10 AbbVie
  7.10.1 AbbVie Corporate Summary
  7.10.2 AbbVie Business Overview
  7.10.3 AbbVie Ulcerative Colitis Treatment Options Major Product Offerings
  7.10.4 AbbVie Ulcerative Colitis Treatment Options Revenue in Global Market (2017-2022)
  7.10.5 AbbVie Key News
7.11 Eli Lilly and Company
  7.11.1 Eli Lilly and Company Corporate Summary
  7.11.2 Eli Lilly and Company Business Overview
  7.11.3 Eli Lilly and Company Ulcerative Colitis Treatment Options Major Product Offerings
  7.11.4 Eli Lilly and Company Ulcerative Colitis Treatment Options Revenue in Global Market (2017-2022)
  7.11.5 Eli Lilly and Company Key News
7.12 Amgen
  7.12.1 Amgen Corporate Summary
  7.12.2 Amgen Business Overview
  7.12.3 Amgen Ulcerative Colitis Treatment Options Major Product Offerings
  7.12.4 Amgen Ulcerative Colitis Treatment Options Revenue in Global Market (2017-2022)
  7.12.5 Amgen Key News
7.13 Takeda Pharmaceuticals Company
  7.13.1 Takeda Pharmaceuticals Company Corporate Summary
  7.13.2 Takeda Pharmaceuticals Company Business Overview
  7.13.3 Takeda Pharmaceuticals Company Ulcerative Colitis Treatment Options Major Product Offerings
  7.13.4 Takeda Pharmaceuticals Company Ulcerative Colitis Treatment Options Revenue in Global Market (2017-2022)
  7.13.5 Takeda Pharmaceuticals Company Key News
7.14 Ferring Pharmaceuticals
  7.14.1 Ferring Pharmaceuticals Corporate Summary
  7.14.2 Ferring Pharmaceuticals Business Overview
  7.14.3 Ferring Pharmaceuticals Ulcerative Colitis Treatment Options Major Product Offerings
  7.14.4 Ferring Pharmaceuticals Ulcerative Colitis Treatment Options Revenue in Global Market (2017-2022)
  7.14.5 Ferring Pharmaceuticals Key News
7.15 InDeX Pharmaceuticals
  7.15.1 InDeX Pharmaceuticals Corporate Summary
  7.15.2 InDeX Pharmaceuticals Business Overview
  7.15.3 InDeX Pharmaceuticals Ulcerative Colitis Treatment Options Major Product Offerings
  7.15.4 InDeX Pharmaceuticals Ulcerative Colitis Treatment Options Revenue in Global Market (2017-2022)
  7.15.5 InDeX Pharmaceuticals Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Ulcerative Colitis Treatment Options Market Opportunities & Trends in Global Market
Table 2. Ulcerative Colitis Treatment Options Market Drivers in Global Market
Table 3. Ulcerative Colitis Treatment Options Market Restraints in Global Market
Table 4. Key Players of Ulcerative Colitis Treatment Options in Global Market
Table 5. Top Ulcerative Colitis Treatment Options Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Ulcerative Colitis Treatment Options Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Ulcerative Colitis Treatment Options Revenue Share by Companies, 2017-2022
Table 8. Global Companies Ulcerative Colitis Treatment Options Product Type
Table 9. List of Global Tier 1 Ulcerative Colitis Treatment Options Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Ulcerative Colitis Treatment Options Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Ulcerative Colitis Treatment Options Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Ulcerative Colitis Treatment Options Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Ulcerative Colitis Treatment Options Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Ulcerative Colitis Treatment Options Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Ulcerative Colitis Treatment Options Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Ulcerative Colitis Treatment Options Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2023-2028
Table 30. Pfizer Corporate Summary
Table 31. Pfizer Ulcerative Colitis Treatment Options Product Offerings
Table 32. Pfizer Ulcerative Colitis Treatment Options Revenue (US$, Mn), (2017-2022)
Table 33. Novartis Corporate Summary
Table 34. Novartis Ulcerative Colitis Treatment Options Product Offerings
Table 35. Novartis Ulcerative Colitis Treatment Options Revenue (US$, Mn), (2017-2022)
Table 36. Roche Corporate Summary
Table 37. Roche Ulcerative Colitis Treatment Options Product Offerings
Table 38. Roche Ulcerative Colitis Treatment Options Revenue (US$, Mn), (2017-2022)
Table 39. Sanofi Corporate Summary
Table 40. Sanofi Ulcerative Colitis Treatment Options Product Offerings
Table 41. Sanofi Ulcerative Colitis Treatment Options Revenue (US$, Mn), (2017-2022)
Table 42. GSK Corporate Summary
Table 43. GSK Ulcerative Colitis Treatment Options Product Offerings
Table 44. GSK Ulcerative Colitis Treatment Options Revenue (US$, Mn), (2017-2022)
Table 45. AstraZeneca Corporate Summary
Table 46. AstraZeneca Ulcerative Colitis Treatment Options Product Offerings
Table 47. AstraZeneca Ulcerative Colitis Treatment Options Revenue (US$, Mn), (2017-2022)
Table 48. MSD Corporate Summary
Table 49. MSD Ulcerative Colitis Treatment Options Product Offerings
Table 50. MSD Ulcerative Colitis Treatment Options Revenue (US$, Mn), (2017-2022)
Table 51. Johnson & Johnson Corporate Summary
Table 52. Johnson & Johnson Ulcerative Colitis Treatment Options Product Offerings
Table 53. Johnson & Johnson Ulcerative Colitis Treatment Options Revenue (US$, Mn), (2017-2022)
Table 54. Bayer Corporate Summary
Table 55. Bayer Ulcerative Colitis Treatment Options Product Offerings
Table 56. Bayer Ulcerative Colitis Treatment Options Revenue (US$, Mn), (2017-2022)
Table 57. AbbVie Corporate Summary
Table 58. AbbVie Ulcerative Colitis Treatment Options Product Offerings
Table 59. AbbVie Ulcerative Colitis Treatment Options Revenue (US$, Mn), (2017-2022)
Table 60. Eli Lilly and Company Corporate Summary
Table 61. Eli Lilly and Company Ulcerative Colitis Treatment Options Product Offerings
Table 62. Eli Lilly and Company Ulcerative Colitis Treatment Options Revenue (US$, Mn), (2017-2022)
Table 63. Amgen Corporate Summary
Table 64. Amgen Ulcerative Colitis Treatment Options Product Offerings
Table 65. Amgen Ulcerative Colitis Treatment Options Revenue (US$, Mn), (2017-2022)
Table 66. Takeda Pharmaceuticals Company Corporate Summary
Table 67. Takeda Pharmaceuticals Company Ulcerative Colitis Treatment Options Product Offerings
Table 68. Takeda Pharmaceuticals Company Ulcerative Colitis Treatment Options Revenue (US$, Mn), (2017-2022)
Table 69. Ferring Pharmaceuticals Corporate Summary
Table 70. Ferring Pharmaceuticals Ulcerative Colitis Treatment Options Product Offerings
Table 71. Ferring Pharmaceuticals Ulcerative Colitis Treatment Options Revenue (US$, Mn), (2017-2022)
Table 72. InDeX Pharmaceuticals Corporate Summary
Table 73. InDeX Pharmaceuticals Ulcerative Colitis Treatment Options Product Offerings
Table 74. InDeX Pharmaceuticals Ulcerative Colitis Treatment Options Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Ulcerative Colitis Treatment Options Segment by Type in 2021
Figure 2. Ulcerative Colitis Treatment Options Segment by Application in 2021
Figure 3. Global Ulcerative Colitis Treatment Options Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Ulcerative Colitis Treatment Options Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Ulcerative Colitis Treatment Options Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Ulcerative Colitis Treatment Options Revenue in 2021
Figure 8. By Type - Global Ulcerative Colitis Treatment Options Revenue Market Share, 2017-2028
Figure 9. By Application - Global Ulcerative Colitis Treatment Options Revenue Market Share, 2017-2028
Figure 10. By Region - Global Ulcerative Colitis Treatment Options Revenue Market Share, 2017-2028
Figure 11. By Country - North America Ulcerative Colitis Treatment Options Revenue Market Share, 2017-2028
Figure 12. US Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Ulcerative Colitis Treatment Options Revenue Market Share, 2017-2028
Figure 16. Germany Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2028
Figure 17. France Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Ulcerative Colitis Treatment Options Revenue Market Share, 2017-2028
Figure 24. China Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2028
Figure 28. India Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Ulcerative Colitis Treatment Options Revenue Market Share, 2017-2028
Figure 30. Brazil Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Ulcerative Colitis Treatment Options Revenue Market Share, 2017-2028
Figure 33. Turkey Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Ulcerative Colitis Treatment Options Revenue, (US$, Mn), 2017-2028
Figure 37. Pfizer Ulcerative Colitis Treatment Options Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Novartis Ulcerative Colitis Treatment Options Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Roche Ulcerative Colitis Treatment Options Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Sanofi Ulcerative Colitis Treatment Options Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. GSK Ulcerative Colitis Treatment Options Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. AstraZeneca Ulcerative Colitis Treatment Options Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. MSD Ulcerative Colitis Treatment Options Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Johnson & Johnson Ulcerative Colitis Treatment Options Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Bayer Ulcerative Colitis Treatment Options Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. AbbVie Ulcerative Colitis Treatment Options Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Eli Lilly and Company Ulcerative Colitis Treatment Options Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Amgen Ulcerative Colitis Treatment Options Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Takeda Pharmaceuticals Company Ulcerative Colitis Treatment Options Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Ferring Pharmaceuticals Ulcerative Colitis Treatment Options Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. InDeX Pharmaceuticals Ulcerative Colitis Treatment Options Revenue Year Over Year Growth (US$, Mn) & (2017-2022)